ROGAINE REVIEW: ADVISORY COMMITTEE CONSIDERS "MEANINGFUL" EFFICACY
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE REVIEW: ADVISORY COMMITTEE CONSIDERS "MEANINGFUL" EFFICACY standard in determining whether Upjohn's prescription baldness product (2% minoxidil) should be available OTC. FDA's Nonprescription Drugs Advisory Committee, supplemented with members of the Dermatologic Drugs and Cardiovascular and Renal Drugs Advisory Committees, met on July 27 and voted 10-4 against recommending Rogaine for over-the-counter use.